Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon
Anne-Marie C
AM
D016363:Antitrust Laws; D003132:Commerce / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D016568:Drugs, Generic / Q000191:economics; D004465:Economic Competition / Q000191:economics / Q000331:legislation & jurisprudence; D017850:Economics, Pharmaceutical; D006801:Humans; D007880:Legislation, Drug; D006278:Medicare / Q000331:legislation & jurisprudence; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D014481:United States; D014485:United States Federal Trade Commission; D014486:United States Food and Drug Administration
D016568:Drugs, Generic